

TiGenix participates in key conferences in the first half of 2015

Leuven (BELGIUM) – 2 February, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the conferences in which it is participating during the first half of 2015.

12-14 January

Biotech Showcase 2015, San Francisco, USA

Presenter: Eduardo Bravo, Chief Executive Officer

26-28 January

Phacilitate Cell and Gene Therapy Conference, Washington, USA

Presenter: Wilfried Dalemans, Chief Technical Officer

3 February

Biotech and Money London 2015, London, UK

Presenter: Eduardo Bravo, Chief Executive Officer

9-10 February

Bio CEO and Investor Conference, New York, USA

Presenter: Eduardo Bravo, Chief Executive Officer

18-21 February

ECCO Inflammatory Bowel Diseases Congress, Barcelona, Spain

Participants: Marie-Paule Richard, Chief Medical Officer; Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; Mary Carmen Diez, Vice President Medical Affairs and New Product Commercialisation

9-11 March

Bio Europe Spring 2015, Paris, France

Participant: Claudia Jimenez, Senior Director Business Development

11 March

Petercam Belgium Investor Day, Milan, Italy

Participant: Claudia D'Augusta, Chief Financial Officer

12 March

EU Advanced Therapies Summit, Paris, France

Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality

17-20 March

International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium

Participant: Marie-Paule Richard, Chief Medical Officer

19 March

KBC Securities Institutional Healthcare Conference, Brussels, Belgium

Participants: Eduardo Bravo, Chief Executive Officer; Claudia D'Augusta, Chief Financial Officer

21 March

FlandersBio KBC Lifescience Retail Investor Event, Leuven, Belgium

Presenter: Wilfried Dalemans, Chief Technical Officer

25 March

ARM Annual Regenerative Medicine Investor Day, New York, USA

Presenter: Eduardo Bravo, Chief Executive Officer

26 March

Bio Capital Amsterdam, Amsterdam, Netherlands

Participant: Claudia D'Augusta, Chief Financial Officer

16 April

Kempen Healthcare and Life Sciences Conference, New York, USA

Participants: Eduardo Bravo, Chief Executive Officer; Claudia D'Augusta, Chief Financial Officer

22 April

Kempen Healthcare and Life Sciences Conference, Amsterdam, Netherlands

Participant: Claudia D'Augusta, Chief Financial Officer

25 April

FedInvest VFB Happening, Brussels, Belgium

Presenter: Eduardo Bravo, Chief Executive Officer

27-28 April

CF&B European Small Cap Event, Paris, France

Participant: Claudia D'Augusta, Chief Financial Officer

16-19 May

Digestive Disease Week, Washington, USA

Participant: Marie-Paule Richard, Chief Medical Officer

20-22 May

Annual World Stem Cell and Regenerative Medicine Congress, London, UK

Participants: Eduardo Bravo, Chief Executive Officer; Claudia Jimenez, Senior Director Business Development

21 May

Knowledge for Growth, Ghent, Belgium

Presenter: Wilfried Dalemans, Chief Technical Officer

2-3 June

PDA Europe Advanced Therapy Medicinal Products Conference, Amsterdam, Netherlands

Moderator: Wilfried Dalemans, Chief Technical Officer

Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality

10-13 June

EULAR Annual European Congress of Rheumatology, Rome, Italy

Participant: Marie-Paule Richard, Chief Medical Officer

15-18 June

Bio International Convention 2015, Philadelphia, USA

Participants: Eduardo Bravo, Chief Executive Officer; Claudia Jimenez, Senior Director Business Development

24-27 June

International Society for Stem Cell Research Annual Meeting, Stockholm, Sweden

Participant: Wilfried Dalemans, Chief Technical Officer

For more information:

Richard Simpson

Senior Consultant, Comfi sprl

T: +32 494 578 278

richard@comfi.be

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two products from this technology platform are currently in clinical

development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and in Phase Ib for severe sepsis. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.